JP2020517255A5 - - Google Patents

Download PDF

Info

Publication number
JP2020517255A5
JP2020517255A5 JP2019556884A JP2019556884A JP2020517255A5 JP 2020517255 A5 JP2020517255 A5 JP 2020517255A5 JP 2019556884 A JP2019556884 A JP 2019556884A JP 2019556884 A JP2019556884 A JP 2019556884A JP 2020517255 A5 JP2020517255 A5 JP 2020517255A5
Authority
JP
Japan
Prior art keywords
nucleic acid
viral vector
acid sequence
engineered
sequence encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019556884A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517255A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/028607 external-priority patent/WO2018195449A1/en
Publication of JP2020517255A publication Critical patent/JP2020517255A/ja
Publication of JP2020517255A5 publication Critical patent/JP2020517255A5/ja
Priority to JP2022145178A priority Critical patent/JP7214915B2/ja
Pending legal-status Critical Current

Links

JP2019556884A 2017-04-21 2018-04-20 Pcsk9遺伝子の認識配列に特異的な操作されたメガヌクレアーゼ Pending JP2020517255A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022145178A JP7214915B2 (ja) 2017-04-21 2022-09-13 Pcsk9遺伝子の認識配列に特異的な操作されたメガヌクレアーゼ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762488403P 2017-04-21 2017-04-21
US62/488,403 2017-04-21
US201762516966P 2017-06-08 2017-06-08
US62/516,966 2017-06-08
PCT/US2018/028607 WO2018195449A1 (en) 2017-04-21 2018-04-20 Engineered meganucleases specific for recognition sequences in the pcsk9 gene

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022145178A Division JP7214915B2 (ja) 2017-04-21 2022-09-13 Pcsk9遺伝子の認識配列に特異的な操作されたメガヌクレアーゼ

Publications (2)

Publication Number Publication Date
JP2020517255A JP2020517255A (ja) 2020-06-18
JP2020517255A5 true JP2020517255A5 (https=) 2021-05-27

Family

ID=62117064

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019556884A Pending JP2020517255A (ja) 2017-04-21 2018-04-20 Pcsk9遺伝子の認識配列に特異的な操作されたメガヌクレアーゼ
JP2022145178A Active JP7214915B2 (ja) 2017-04-21 2022-09-13 Pcsk9遺伝子の認識配列に特異的な操作されたメガヌクレアーゼ
JP2023005733A Pending JP2023058509A (ja) 2017-04-21 2023-01-18 Pcsk9遺伝子の認識配列に特異的な操作されたメガヌクレアーゼ
JP2024231599A Pending JP2025066725A (ja) 2017-04-21 2024-12-27 Pcsk9遺伝子の認識配列に特異的な操作されたメガヌクレアーゼ

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022145178A Active JP7214915B2 (ja) 2017-04-21 2022-09-13 Pcsk9遺伝子の認識配列に特異的な操作されたメガヌクレアーゼ
JP2023005733A Pending JP2023058509A (ja) 2017-04-21 2023-01-18 Pcsk9遺伝子の認識配列に特異的な操作されたメガヌクレアーゼ
JP2024231599A Pending JP2025066725A (ja) 2017-04-21 2024-12-27 Pcsk9遺伝子の認識配列に特異的な操作されたメガヌクレアーゼ

Country Status (11)

Country Link
US (4) US11680254B2 (https=)
EP (2) EP3612205B9 (https=)
JP (4) JP2020517255A (https=)
KR (2) KR102620399B1 (https=)
CN (2) CN117264929A (https=)
AU (2) AU2018254576B2 (https=)
CA (1) CA3060112A1 (https=)
ES (1) ES2953153T3 (https=)
IL (3) IL324738A (https=)
MX (2) MX2019012452A (https=)
WO (1) WO2018195449A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020214724A1 (en) * 2019-04-15 2020-10-22 The Trustees Of The University Of Pennsylvania Compositions for regulating and self-inactivating enzyme expression and methods for modulating off-target activity of enzymes
CA3137975A1 (en) 2019-05-07 2020-11-12 Precision Biosciences, Inc. Optimization of engineered meganucleases for recognition sequences
WO2021222249A1 (en) * 2020-04-27 2021-11-04 The Trustees Of The University Of Pennsylvania Compositions and methods for reducing nuclease expression and off-target activity using a promoter with low transcriptional activity
WO2021222238A1 (en) * 2020-04-27 2021-11-04 The Trustees Of The University Of Pennsylvania Compositions and methods for reducing nuclease expression and off-target activity using a promoter with low transcriptional activity
US20230183664A1 (en) 2020-05-11 2023-06-15 Precision Biosciences, Inc. Self-limiting viral vectors encoding nucleases
US20230304034A1 (en) 2020-05-12 2023-09-28 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
AU2021369793A1 (en) 2020-10-29 2023-06-08 The Trustees Of The University Of Pennsylvania Aav capsids and compositions containing same
CA3172481A1 (en) * 2020-11-12 2022-05-19 Precision Biosciences, Inc. Engineered meganucleases having specificity for recognition sequences in the dystrophin gene
US20240197916A1 (en) * 2021-04-27 2024-06-20 The Trustees Of The University Of Pennsylvania Compositions and methods for in vivo nuclease-mediated gene targeting for the treatment of genetic disorders
TW202309066A (zh) 2021-04-27 2023-03-01 賓州大學委員會 衍生自豬的腺相關病毒衣殼及其用途
WO2023087019A2 (en) 2021-11-15 2023-05-19 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
WO2023240076A1 (en) 2022-06-07 2023-12-14 Scribe Therapeutics Inc. Compositions and methods for the targeting of pcsk9
WO2024015966A2 (en) 2022-07-15 2024-01-18 The Trustees Of The University Of Pennsylvania Recombinant aav having aav clade d and clade e capsids and compositions containing same
WO2025122552A1 (en) * 2023-12-04 2025-06-12 The Trustees Of The University Of Pennsylvania In silico prediction tool for meganuclease off-target sites

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5652224A (en) * 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US6555674B2 (en) 2000-08-09 2003-04-29 Nsgene A/S JeT promoter
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
US20060153826A1 (en) 2003-01-28 2006-07-13 Sylvain Arnould Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
CA2891996A1 (en) 2005-10-18 2007-04-26 Duke University Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity
ES2366973T3 (es) * 2006-05-05 2011-10-27 Isis Pharmaceuticals, Inc. Compuestos y procedimiento para modular la expresión génica.
AU2013201688B2 (en) * 2006-11-07 2016-03-03 Merck Sharp & Dohme Llc Antagonists of PCSK9
AU2013203748C1 (en) * 2007-08-23 2017-05-25 Amgen Inc. Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)
CA2603615A1 (en) * 2007-09-21 2009-03-21 Patrick Labonte Methods of reducing viral infection and kits therefore
EP2215223B1 (en) 2007-10-31 2013-05-01 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
US7928189B2 (en) * 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
DK3211075T3 (en) 2008-07-14 2019-01-21 Prec Biosciences Inc RECOGNITION SEQUENCES FOR I-CREI-DERIVED MECHANUCLEASES AND APPLICATIONS THEREOF
EP2180058A1 (en) * 2008-10-23 2010-04-28 Cellectis Meganuclease recombination system
AU2013273674B2 (en) * 2009-09-03 2015-11-05 Pfizer Vaccines Llc PCSK9 vaccine
DK2714936T3 (en) 2011-06-01 2019-03-25 Prec Biosciences Inc METHODS AND PRODUCTS FOR PRODUCING MANIPULATED MAMMAL CELL LINES WITH AMPLIFIED TRANSGENES
EP4331620A3 (en) * 2012-12-07 2024-12-04 Translate Bio, Inc. Lipidic nanoparticles for mrna delivery
RU2694686C2 (ru) * 2013-03-12 2019-07-16 Е.И.Дюпон Де Немур Энд Компани Способы идентификации вариантных сайтов распознавания для редкощепящих сконструированных средств для индукции двунитевого разрыва, и композиции с ними, и их применения
MX2015017312A (es) 2013-06-17 2017-04-10 Broad Inst Inc Suministro y uso de composiciones, vectores y sistemas crispr-cas para la modificación dirigida y terapia hepáticas.
AU2015217301A1 (en) * 2014-02-11 2016-08-25 Alnylam Pharmaceuticals, Inc. Ketohexokinase (KHK) iRNA compositions and methods of use thereof
ES2876409T3 (es) * 2014-04-25 2021-11-12 Univ Pennsylvania Variantes del RLBD y su uso en composiciones para reducir los niveles de colesterol
AU2015259191B2 (en) * 2014-05-13 2019-03-21 Sangamo Therapeutics, Inc. Methods and compositions for prevention or treatment of a disease
US10603363B2 (en) * 2015-09-08 2020-03-31 Precision Biosciences, Inc. Treatment of retinitis pigmentosa using engineered meganucleases
CN117070468A (zh) * 2015-10-05 2023-11-17 精密生物科学公司 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞

Similar Documents

Publication Publication Date Title
JP2020517255A5 (https=)
JP2019530462A5 (https=)
JP2018537087A5 (https=)
JP2004512020A5 (https=)
JP2015096070A5 (https=)
JP2018515096A5 (https=)
FI3872085T3 (fi) Esimuotoiset virussekvenssit ja niiden käytöt
JP2012095652A5 (https=)
Ferrer-Miralles et al. Biological activities of histidine-rich peptides; merging biotechnology and nanomedicine
JP2020508667A5 (https=)
JP2016052331A5 (https=)
JP2012532601A5 (https=)
JP2005120106A5 (https=)
JP2020520662A5 (https=)
JP2021518139A5 (https=)
JP2013521789A5 (https=)
JP2014239686A5 (https=)
JP2015501840A5 (https=)
JP2003522514A5 (https=)
JP2016521539A5 (https=)
WO2006063101A3 (en) Vaccines for the rapid response to pandemic avian influenza
JP2014198050A5 (https=)
JP2003503355A5 (https=)
CN116113702A (zh) 一种融合蛋白及其用途
WO2023010120A3 (en) Engineering aav vectors with improved cns targeting